Gallic Acid Reduces Blood Pressure and Attenuates Oxidative Stress and Cardiac Hypertrophy in Spontaneously Hypertensive Rats

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Jin, Li ^a,b   Piao, Zhe Hao ^c   Sun, Simei ^a   Liu, Bin ^c   Kim, Gwi Ran ^a   Seok, Young Mi ^d   Lin, Ming Quan ^e   Ryu, Yuhee ^a   Choi, Sin Young ^a   Kee, Hae Jin ^a   Jeong, Myung Ho ^a  

^a Chonnam National University Medical School   (South Korea)

^b Affiliated Jilin Hospital of Jilin University   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d National Development Institute of Korea Medicine   (South Korea)

^e YANBIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; GALLIC ACID; GATA4 PROTEIN, RAT; HOMEOBOX PROTEIN NKX-2.5; NKX2.5 PROTEIN, RAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSCRIPTION FACTOR GATA 4;

ANIMAL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOMEGALY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEART; HUMAN; HYPERTENSION; MALE; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOMEGALY; GALLIC ACID; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HEART; HOMEOBOX PROTEIN NKX-2.5; HUMANS; HYPERTENSION; MALE; NADPH OXIDASE 2; OXIDATIVE STRESS; RATS; RATS, INBRED SHR;

EID: 85034421842     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-15925-1     Document Type: Article

References (63)

1. Mensah, G. A., Croft, J. B. & Giles, W. H. The heart, kidney, and brain as target organs in hypertension. Cardiol Clin 20, 225-247 (2002).
2. Verdecchia, P. et al. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? J Hum Hypertens 18(Suppl 2), S23-28 (2004).
3. Marwick, T. H. et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)dagger. Eur Heart J Cardiovasc Imaging 16, 577-605 (2015).
4. Julien, J., Tranche, C. & Souchet, T. [Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis]. Arch Mal Coeur Vaiss 97, 221-227 (2004).
5. Bianchi, G. et al. Genetic and experimental hypertension in the animal model-similarities and dissimilarities to the development of human hypertension. J Cardiovasc Pharmacol 8(Suppl 5), S64-70 (1986).
6. Doggrell, S. A. & Brown, L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39, 89-105 (1998).
7. Oparil, S., Zaman, M. A. & Calhoun, D. A. Pathogenesis of hypertension. Ann Intern Med 139, 761-776 (2003).
8. Dyer, A. R. & Elliott, P. The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group. J Hum Hypertens 3, 299-308 (1989).
9. Woodiwiss, A. J. & Norton, G. R. Obesity and left ventricular hypertrophy: the hypertension connection. Curr Hypertens Rep 17, 539 (2015).
10. Salvetti, G. et al. Prevalence of left ventricular hypertrophy and determinants of left ventricular mass in obese women. High Blood Press Cardiovasc Prev 19, 33-39 (2012).
11. De Leeuw, P. W. How do angiotensin II receptor antagonists affect blood pressure? Am J Cardiol 84, 5K-6K (1999).
12. Kagiyama, S. et al. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106, 909-912 (2002).
13. Takimoto, E. & Kass, D. A. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49, 241-248 (2007).
14. Panday, A., Sahoo, M. K., Osorio, D. & Batra, S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol 12, 5-23 (2015).
15. El-Benna, J., Dang, P. M., Gougerot-Pocidalo, M. A., Marie, J. C. & Braut-Boucher, F. p47phox, the phagocyte NADPH oxidase/ NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 41, 217-225 (2009).
16. Cave, A., Grieve, D., Johar, S., Zhang, M. & Shah, A. M. NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond B Biol Sci 360, 2327-2334 (2005).
17. Sinha, N. & Dabla, P. K. Oxidative stress and antioxidants in hypertension-a current review. Curr Hypertens Rev 11, 132-142 (2015).
18. Drummond, G. R. & Sobey, C. G. Endothelial NADPH oxidases: which NOX to target in vascular disease? Trends Endocrinol Metab 25, 452-463 (2014).
19. Montezano, A. C. et al. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol 31, 631-641 (2015).
20. Zhao, W., Zhao, T., Chen, Y., Ahokas, R. A. & Sun, Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 317, 43-50 (2008).
21. Seddon, M., Looi, Y. H. & Shah, A. M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93, 903-907 (2007).
22. Patel, S. S. & Goyal, R. K. Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. Pharmacognosy Res 3, 239-245 (2011).
23. Shao, D. et al. Inhibition of Gallic Acid on the Growth and Biofilm Formation of Escherichia coli and Streptococcus mutans. J Food Sci 80, M1299-1305 (2015).
24. Wang, K., Zhu, X., Zhang, K., Zhu, L. & Zhou, F. Investigation of gallic acid induced anticancer effect in human breast carcinoma MCF-7 cells. J Biochem Mol Toxicol 28, 387-393 (2014).
25. Jung, H. J. & Lim, C. J. The antiangiogenic and antinociceptive activities of n-propyl gallate. Phytother Res 25, 1570-1573 (2011).
26. Choubey, S., Varughese, L. R., Kumar, V. & Beniwal, V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal 4, 305-315 (2015).
27. Mansouri, M. T. et al. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food Chem 138, 1028-1033 (2013).
28. Stanely Mainzen Prince, P., Priscilla, H. & Devika, P. T. Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in Wistar rats. Eur J Pharmacol 615, 139-143 (2009).
29. Kee, H. J. et al. Gallic acid inhibits vascular calcification through the blockade of BMP2-Smad1/5/8 signaling pathway. Vascul Pharmacol 63, 71-78 (2014).
30. Choi, S. Y. et al. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol 72, 130-140 (2015).
31. Ryu, Y. et al. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. Sci Rep 6, 34790 (2016).
32. Seok, Y. M., Jang, E. J., Reiser, O., Hager, M. & Kim, I. K. 17beta-Estradiol induces vasorelaxation in a G-protein-coupled receptor 30-independent manner. Naunyn Schmiedebergs Arch Pharmacol 385, 945-948 (2012).
33. Seok, Y. M. et al. Enhanced Ca2+ -dependent activation of phosphoinositide 3-kinase class IIalpha isoform-Rho axis in blood vessels of spontaneously hypertensive rats. Hypertension 56, 934-941 (2010).
34. Kee, H. J. et al. Enhancer ofpolycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation. J Biol Chem 282, 7700-7709 (2007).
35. Hall, J. E. The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther 17, 8-17 (1991).
36. Sen, S., Tarazi, R. C., Khairallah, P. A. & Bumpus, F. M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 35, 775-781 (1974).
37. Kohli, S., Ahuja, S. & Rani, V. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr Cardiol Rev 7, 262-271 (2011).
38. Fan, X. et al. Novel mechanism of intrarenal angiotensin II-induced sodium/proton exchanger 3 expression by losartan in spontaneously hypertensive rats. Mol Med Rep 10, 2483-2488 (2014).
39. Castro-Moreno, P. et al. Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR. Auton Autacoid Pharmacol 32, 61-69 (2012).
40. Datla, S. R. & Griendling, K. K. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 56, 325-330 (2010).
41. Kang, N. et al. Gallic acid isolated from Spirogyra sp. improves cardiovascular disease through a vasorelaxant and antihypertensive effect. Environ Toxicol Pharmacol 39, 764-772 (2015).
42. Schuchard, J. et al. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Br J Pharmacol 172, 3764-3778 (2015).
43. Akazawa, H. & Komuro, I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92, 1079-1088 (2003).
44. Liang, Q. et al. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276, 30245-30253 (2001).
45. Wind, S. et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 56, 490-497 (2010).
46. Romero, M. et al. Antihypertensive effects of oleuropein-enriched olive leaf extract in spontaneously hypertensive rats. Food Funct 7, 584-593 (2016).
47. Abid, M. R., Spokes, K. C., Shih, S. C. & Aird, W. C. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 282, 35373-35385 (2007).
48. Miguel-Carrasco, J. L. et al. Blockade of TGF-beta 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. Oxid Med Cell Longev 2012, 726940 (2012).
49. Briones, A. M. et al. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertens 5, 137-153 (2011).
50. Li, H. et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 47, 2536-2544 (2006).
51. Chabrashvili, T. et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39, 269-274 (2002).
52. Paravicini, T. M., Chrissobolis, S., Drummond, G. R. & Sobey, C. G. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 35, 584-589 (2004).
53. Sag, C. M., Santos, C. X. & Shah, A. M. Redox regulation of cardiac hypertrophy. J Mol Cell Cardiol 73, 103-111 (2014).
54. Li, J. M., Gall, N. P., Grieve, D. J., Chen, M. & Shah, A. M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477-484 (2002).
55. Krijnen, P. A. et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 56, 194-199 (2003).
56. Brewer, A. C., Sparks, E. C. & Shah, A. M. Transcriptional regulation of the NADPH oxidase isoform, Nox1, in colon epithelial cells: role of GATA-binding factor(s). Free Radic Biol Med 40, 260-274 (2006).
57. Riazi, A. M. et al. NKX2-5 regulates the expression of beta-catenin and GATA4 in ventricular myocytes. PLoS One 4, e5698 (2009).
58. Lee, Y. et al. The cardiac tissue-restricted homeobox protein Csx/Nkx2.5 physically associates with the zinc finger protein GATA4 and cooperatively activates atrial natriuretic factor gene expression. Mol Cell Biol 18, 3120-3129 (1998).
59. Ramya, K., Mohandas, S. R. & Ashok, K. J. Evaluation of diuretic activity of gallic acid in normal rats. J Sci Innov Res 3, 217-220 (2014).
60. Li, H. et al. Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy. Am J Physiol Heart Circ Physiol 298, H688-698 (2010).
61. Prasad, A. M. et al. Calcium/calmodulin-dependent kinase II inhibition in smooth muscle reduces angiotensin II-induced hypertension by controlling aortic remodeling and baroreceptor function. J Am Heart Assoc 4, e001949 (2015).
62. Hagemann, D., Bohlender, J., Hoch, B., Krause, E. G. & Karczewski, P. Expression of Ca2+/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy. Mol Cell Biochem 220, 69-76 (2001).
63. Yi, Q. Y. et al. Chronic infusion of epigallocatechin-3-O-gallate into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation by restoring neurotransmitters and cytokines. Toxicol Lett 262, 105-113 (2016).